About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
2020 ASCO Virtual Direct™ Highlights
Boston
Breast
GYN
Lung
GI
GU
Skin
Hematologic Oncology
Head&Neck
Supportive/Palliative Care
St. Louis
Breast
GYN
Lung
GI
GU
Skin
Hematologic Oncology
Head&Neck
Supportive/Palliative Care
Basic Science
Jacksonville
Breast
Hematologic Oncology
Lung
GI
GU
GYN
Skin
Head&Neck
Basic Science
Philadelphia
GI
GU
Lung
Skin
Hematologic Oncology
Breast
Supportive/Palliative Care
Head&Neck
GYN
Denver
Breast
Hematologic Oncology
Lung
GU
Skin
GYN
Head&Neck
Basic Science
San Francisco
Breast
Lung
GU
Hematologic Oncology
Skin
GI
GYN
Head&Neck
Business
Las Vegas
GI
GU
Hematologic Oncology
Skin
Lung
Head&Neck
GYN
Business
San Juan
Breast
GI
Hematologic Oncology
Skin
GYN
Basic Science
Head and Neck
Supportive and Palliative Care
Business
Events
Head&Neck
10:06
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Updates on HPV+ Oropharynx Cancer: Can TORS and Reduced Dose Post-Operative RT Maintain High Cure Rates and Decrease Late Toxicity in Intermediate Risk Disease?
FEATURING
Deborah Wong
11 views
September 29, 2020
13:56
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Updates for High-Risk SCCHN: Is Post-Operative Weekly Cisplatin 40mg/m2 Inferior to Bolus Cisplatin With RT?
FEATURING
Deborah Wong
31 views
September 29, 2020
17:05
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on Solid H&N Tumors With HRAS Mutations: Is Tipifarnib a Good Option for Post-Chemo Patients With SCCHN? Does Axitinib Improve Overall Outcomes?
FEATURING
Deborah Wong
20 views
September 29, 2020